A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata

The study found that a single subcutaneous dose of BMD-1141, a compound targeting hair regrowth, was as effective as daily high-dose ruxolitinib in a mouse model of alopecia areata. Involving 80 mice, the study showed that BMD-1141 increased anagen hair follicles and stimulated hair regrowth without triggering an autoimmune response, as indicated by increased beta-catenin levels. BMD-1141's long tissue residence allows for less frequent dosing, potentially every 1-3 months, compared to daily JAK inhibitors. The treatment was well-tolerated, with no significant adverse effects, suggesting BMD-1141 as a promising alternative for alopecia areata treatment, avoiding systemic immunosuppression. Future clinical studies are needed to confirm optimal dosing and long-term safety.